GO
Loading...

Pharmaceuticals

More

  • CNBC's Schacknow: Huckman's Crystal Ball Tuesday, 19 Jun 2007 | 3:04 PM ET

    We can’t all be experts at everything, which is why we have people who are experts at something. Having said that, I’ll let you in on one of my little secrets -- how to tell when a pharmaceutical story has significance. ... Also: a seemingly innocuous headline -- about Expedia -- has plenty of hidden meaning.

  • A More "Crystal" Bristol-Myers After Ruling Tuesday, 19 Jun 2007 | 2:23 PM ET

    Bristol-Myers Squibb's future looks a lot clearer. A federal judge this morning ruled the patent on the bloodthinner Plavix which Bristol shares with Sanofi-Aventis is valid. And Judge Sidney Stein added the companies are entitled to injunctive relief and damages. Money. It'll come from the scrappy, pesky, Canadian, privately-held generic drug company "Apotex". Last summer Apotex took advantage of a legal loophole in a sweet side deal it negotiated with Bristol and launched generic Plavix.

  • A U.S. judge on Tuesday ruled that the patent on the multibillion-dollar blood clot-preventing drug Plavix is valid, handing a major victory to Bristol-Myers Squibb and Sanofi-Aventis.

  • Shares of Bristol, Sanofi Rise On Plavix Ruling Tuesday, 19 Jun 2007 | 11:18 AM ET

    A U.S. judge Tuesday ruled that the patent on the multibillion-dollar blood clot preventer Plavix is valid, handing a major victory to Bristol-Myers Squibb and Sanofi-Aventis. Shares of both companies rose on the news.

  • Bristol Breast Cancer Drug Granted Priority FDA Review Tuesday, 19 Jun 2007 | 8:22 AM ET

    U.S. health regulators have granted priority review for Bristol-Myers Squibb experimental breast cancer drug ixabepilone, and an approval decision on the medicine could come by late October, the company said on Tuesday.

  • Earnings news and clinical trial data were some of the catalysts behind the most actively traded stocks on Monday.

  • GlaxoSmithKline plans to launch five new cancer drugs by 2010, tapping into a $40 billion-a-year market that is growing by 20 percent annually, its research head said on Monday.

  • A Biotech Buy for the Bold Friday, 15 Jun 2007 | 8:00 PM ET

    If CV Therapeutics doubles, take profits. If it gets clobbered, at least the company’s best drug can treat your angina.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Gilead Sciences shares rose in aftermarket trading on Friday after the U.S. Food and Drug Administration approved the drugmaker's treatment for high blood pressure in the lungs.

  • Double D: Diets and Dendreon Thursday, 14 Jun 2007 | 2:54 PM ET
    Alli Diet Pills

    Today's the day! Wal-Mart starts selling the first FDA-approved, over-the-counter weightloss pill today. GlaxoSmithKline says Alli should be on drugstore and discount store shelves everywhere by tomorrow. Alli is the diet pill that can have embarrassing gastrointestinal side effects. Coincidentally, the launch occurs the day after an FDA Advisory Committee shut out Sanofi-Aventis' weightloss pill Zimulti.

  • Analyst actions and corporate announcements were some of the catalysts behind the most actively traded stocks on Thursday.

  • Investors wiped some 6 billion euros ($7.97 billion) off the market value of French pharmaceutical company Sanofi-Aventis Thursday after U.S. federal health advisers rejected its Accomplia weight-loss drug.

  • Analyst actions and clinical trial data were some of the catalysts behind the most actively traded stocks on Wednesday.

  • Novartis Gets EU OK for New Flu Vaccine Wednesday, 13 Jun 2007 | 4:25 AM ET

    Swiss drugmaker Novartis said Wednesday it has received European Union approval for flu vaccine Optaflu.

  • Buying Big Pharma - If You Must Tuesday, 12 Jun 2007 | 7:03 PM ET

    It’s slim pickings in the sector, but there are a couple of stocks that are actually worth buying, Cramer says.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Knowin' When to Hold 'Em Tuesday, 12 Jun 2007 | 7:01 PM ET

    If you’re dead set on cradling your drugmaker darlings, there are only a few Cramer thinks are worth owning.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Big Pharma Is Bad Investing Tuesday, 12 Jun 2007 | 7:00 PM ET

    Without patents or pipeline, drug companies just don't have the growth investors crave anymore. Cramer tells you who to avoid.Investing can be confusing. Luckily, Cramer has mapped out some road rules for all you Home Gamers trying to navigate the jungle that is Wall Street. Think of it as "Mad Money 101" –- some fundamental advice to keep in mind as you play the market. Whether you're a first time investor or a seasoned financier, it's always good to remember the basics.

  • Analyst actions and earnings news were some of the catalysts behind the most actively traded stocks on Tuesday. Financial stocks were in focus and Lehman Brothers rose on heavy trading volume after the investment banking firm reported strong quarterly earnings.

  • Glaxo Faces U.S. Investor Lawsuit Over Avandia Tuesday, 12 Jun 2007 | 12:02 PM ET

    GlaxoSmithKline faces a U.S. investor lawsuit claiming that Europe's biggest drugmaker misled shareholders about the safety of diabetes drug Avandia.

  • European Stocks to Watch: GlaxoSmithKline Tuesday, 12 Jun 2007 | 12:01 PM ET

    Shares in GlaxoSmithKline fell 0.4% as the British pharmaceutical giant came under fire for allegedly misleading its shareholders about safety concerns facing its diabetes drug Avandia.